RBC on Pfizer (PFE): 'Litigation overhang cleared'
Tweet Send to a Friend
RBC Capital analyst Trung Huynh reiterated an Underperform rating and $25.00 price target on Pfizer (NYSE: PFE).The analyst comments "Our ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


